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ABSTRACT
Several important viruses including the human im-
munodeficiency virus type 1 (HIV-1) and the SARS-
associated Coronavirus (SARS-CoV) employ
programmed  1 ribosomal frameshifting (PRF) for
their protein expression. Here, a kinetic framework
is developed to describe  1 PRF. The model reveals
three kinetic pathways to  1 PRF that yield two
possible frameshift products: those incorporating
zero frame encoded A-site tRNAs in the recoding
site, and products incorporating  1 frame encoded
A-site tRNAs. Using known kinetic rate constants,
the individual contributions of different steps of
the translation elongation cycle to  1 PRF and the
ratio between two types of frameshift products were
evaluated. A dual fluorescence reporter was
employed in Escherichia coli to empirically test the
model. Additionally, the study applied a novel mass
spectrometry approach to quantify the ratios of the
two frameshift products. A more detailed under-
standing of the mechanisms underlying  1 PRF
may provide insight into developing antiviral
therapeutics.
INTRODUCTION
Programmed ribosomal frameshifting (PRF) is a process
where speciﬁc signals in the mRNA direct the ribosome to
switch reading frame at a certain efﬁciency. In  1 PRF,
the ribosome slips 1nt towards the 50-end of the mRNA
during translation. Several viruses, including human im-
munodeﬁciency virus type 1 (HIV-1) and the coronavirus
responsible for severe acute respiratory syndrome
(SARS-CoV), employ  1 PRF to synthesize precursors
of enzymes for their replication (1,2), and the ratio of
the zero frame to  1 frame encoded products is important
to the vitality of viruses (3–5). As such, altering  1 PRF
efﬁciency may damage viral replication [reviewed in (6)].
This suggests  1 PRF as a target for the development of
antiviral therapeutics.
Programmed  1 ribosomal frameshifting signals
usually contain three essential mRNA elements: (i) a
‘slippery’ heptanucleotide sequence X XXY YYZ (X can
be any three identical nucleotides, Y is A or U and Z is
not G in eukaryotes; spaces denote the initial reading
frame), where the ribosome changes the reading frame
(3,7); (ii) a downstream stimulatory mRNA secondary
structure, typically a pseudoknot (8–10); and (iii) a
spacer between the slippery sequence and the stimulatory
signal. It has been suggested that the stimulatory struc-
tural element promotes  1 PRF by positioning the
ribosome to pause over the slippery sequence (11–13).
The length of the spacer has also been shown to affect
frameshift efﬁciency (7,9,14).
As PRF occurs during translation elongation, models of
 1 PRF should be described within this context. The
elongation cycle can be divided into four stages. First,
the ribosome selects the cognate aminoacyl-tRNA
(aa-tRNA) according to the codon at the decoding
center (decoding, DC in Figure 1). Second, the aa-tRNA
moves from A/T entry state into the A/A state to be
accommodated into the ribosome (aa-tRNA accommoda-
tion, AA in Figure 1). Third, the ribosome catalyses
peptidyltransfer, resulting in a peptidyl tRNA in the
A-site and a deacylated tRNA in the P site
(peptidyltransfer, PT in Figure 1). Fourth, the peptidyl-
tRNA moves from the A-site to the P-site, carrying the
mRNA along, and the deacylated tRNA moves out of the
P-site into the E-site from where it dissociates (transloca-
tion, TL in Figure 1). Translocation opens up the riboso-
mal A-site and the ribosome moves on to another round
of aa-tRNA selection.
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anism of  1 PRF (Figure 1). One hypothesis proposes
that  1 PRF takes place during accommodation of the
aa-tRNA (8,15,16). We have denoted this Pathway II. The
simultaneous-slippage model (8) originally suggested that
peptidyl- and aa-tRNAs simultaneously slip by one base
in the 50-direction to base pair with the  1 frame codons
in the slippery site. In a reﬁnement of this model (15),  1
PRF was posited to occur when aa-tRNA and
peptidyl-tRNA are located in the A/T entry and P/P
site. The 9-A ˚ model of  1 PRF (16) built upon both
this and newly available structural data to propose that
the  9-A ˚ movement of the anticodon loop in the
50-direction during aa-tRNA accommodation is con-
strained by the presence of the downstream stimulatory
RNA structural element. This creates tension on the
mRNA between the decoding center and the stimulatory
element that can be relieved by decoupling of the A- and
P-site tRNAs from the mRNA followed by subsequent
slippage of the mRNA by one base in the 30-direction
relative to the tRNAs, resulting in a net slip reading
frame by  1 base. Consistent with this model, mutations
altering aa-tRNA accommodation were found to affect
 1 PRF (18–20). However, the simultaneous
slippage-based models do not explain the role of sequences
upstream of the slippery site, which have also been shown
to affect the  1 PRF efﬁciency (21,22). A second general
hypothesis proposes that  1 PRF occurs during trans-
location. This can be modeled through two discrete
kinetic pathways. The ﬁrst suggested that after
peptidyltransfer, the two tRNAs move to P/E and A/P
states, followed by an incomplete, two-base translocation
event promoted by the downstream mRNA stimulatory
structure (23). During this incomplete translocation
event, the tRNAs dissociate from the mRNA and
re-pair with the  1 frame codons in the slippery site.
We call this Pathway III. In support of this model,
cryoelectron microscopy imaging revealed that a  1
PRF stimulating pseudoknot can interact with the
ribosome to block the mRNA entrance channel,
compromising the translocation process during  1 PRF
(24). The second co-translocational model proposed that
incomplete translocation occurs one elongation cycle prior
to the model by Weiss et al. (23), and that tRNAs in the
ribosomal E-, P- and A-sites are all involved in the process
(22). This model suggests that incomplete translocation
promotes formation of a transition intermediate, and
that entry of the new aa-tRNA into the ribosome and
the tendency of tRNAs to revert to stable states drives
the shift in reading frame. This is Pathway I. This model
is supported by the demonstration that mutations altering
E-site tRNA binding affect  1 PRF (22). However,
Figure 1. A mechanistic model of –1 programmed ribosomal frameshifting. Two translation elongation cycles are depicted at the top: the ribosome
undergoes decoding (DC), aa-tRNA accommodation (AA), peptidyltransfer (PT) and translocation (TL) twice to add two amino acids into the
polypeptide sequences. A shift in reading frame may occur at the ﬁrst TL step and the ribosome decodes a  1 frame A-site codon at the recoding
site. Additionally,  1 PRF may occur during the second AA step, in which the ribosome has decoded the zero frame A-site codon. Incorporation of
the  1 reading frame aa-tRNA starts at the following cycle. Moreover, the shift in reading frame may occur at the second TL step and incorporation
of the  1 reading frame aa-tRNA starts at the following cycle.
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presence of two species of frameshift proteins produced
by HIV-1 frameshifting (see next paragraph).
Protein sequencing was originally employed to generate
the simultaneous slippage model, and to conﬁrm that the
 1PRFsiteforHIV-1isUUUUUUAlocatedwithinthegag/
pol overlap (where the P-site of the ribosome during frame-
shifting is underlined) (1). Interestingly,  70% of the
frameshift products contained Phe-Leu (derived from
decoding the 0-frame UUU UUA sequence), while  30% of
the products contained Phe–Phe (derived from decoding
the  1 frame UUU UUU sequence) at the frameshift site
(1,25). Previous studies suggested that the product with
Phe–Phe at the frameshift site could result from slippage
of the P-site tRNA alone (1,25,26), i.e. the product pre-
dicted by Pathway I, and that the  1 frame aa-tRNA is
subsequently recruited to the ribosome. However, the
precise mechanism driving this process remained unclear,
and no model has been proposed to date explaining the
simultaneous formation of different frameshift proteins.
Here, we have developed a kinetic model of  1 PRF to
explain all of the experimental observations. This model
reveals the major steps in the translation elongation cycle
that affect  1 PRF, and reconciles all three models of  1
PRF. In addition,  1 PRF efﬁciency was monitored in vivo
using a dual ﬂuorescence reporter (27) and the compos-
itions of different frameshift proteins were analysed by
mass spectrometry. The experimental approach was also
applied to study Human T-cell leukemia virus type 1
(HTLV) pro-pol frameshift sequence. This is the ﬁrst
study to demonstrate and quantify the ratio of frameshift
products incorporating  1 frame A-site tRNA at this  1
PRF sequence. In agreement with the model predictions,
experimental perturbation of different translation steps
resulted in different levels of  1 PRF efﬁciency as well as
in the relative ratios of two types of frameshift proteins.
Our ﬁndings demonstrate that all three kinetic pathways
are operative during  1 PRF.
Kinetic model
In our earlier study, a kinetic model successfully described
the effects of ribosome E-, P- and A-site interactions on
+1 PRF (27). A similar approach can be applied to under-
stand the mechanism of  1 PRF. The mechanistic model
in the present study proposes that  1 PRF can occur
during translocation and/or aa-tRNA accommodation.
Figure 1 describes the overall framework using abc deX
XXY YYZ fgh sequence as an example, where spaces
separate zero frame codons and the slippery sequence is
underlined. When  1 PRF occurs during translocation,
the presence of the downstream stimulatory structure
forces the ribosome to translocate by two, rather than
three, bases toward the 30-end of the mRNA, thus
shifting the reading frame. If this ‘incomplete’ transloca-
tion occurs to the pre-translocational ribosome aligning
with deX XXY, translation of the  1 frame begins at
YYY. Alternatively, if incomplete translocation occurs to
the pre-translocational ribosome aligning with XXY YYZ,
translation of the  1 frame starts at Zfg. When  1 PRF
occurs during aa-tRNA accommodation, the two tRNAs
interacting with XXY YYZ slip to base pair with XXX YYY.
Consequently, translation of  1 frame starts at Zfg
(Figure 1).
An elegant series of biochemical analyses have estab-
lished detailed kinetic models of translocation (28) and
aa-tRNA selection (29). Translocation involves EF-G
binding to the pre-translocational ribosome, GTP hydroly-
sis, unlocking conformation change, Pi release, tRNA
movement, relocking conformation change and dissoci-
ation of EF-G from the post-translocational ribosome.
This concept is illustrated along the top of Figure 2 from
component PA (pre-translocational ribosome) to E0P0
(post-translocational ribosome). Detailed descriptions for
each rate constant are shown in Supplementary Table S1.
Selection and accommodation of aa-tRNA involves initial
binding of the ternary complex EF-Tu:aa-tRNA:GTP,
codon recognition, EF-Tu GTPase activation, GTP
hydrolysis, dissociation of EF-Tu from the ribosome and
accommodation of the acceptor end of the aa-tRNA into
the A-site or the rejection of the aa-tRNA by proofreading.
Detailed descriptions for each rate constant are shown in
Supplementary Table S2. In the absence of frameshifting,
progression through these steps of the elongation cycle
results in synthesis of the non-frameshift protein, called
NFS (Figure 2).
Our kinetic model suggests three possible reaction
pathways that could generate  1 frameshift proteins
(Figure 2). In Pathway I, blockage of the mRNA channel
entrance by the downstream stimulatory structure induces
incomplete translocation with the pre-translocational
ribosome positioned at deX XXY. Speciﬁcally, the reading
frame shift occurs between the tRNA movement and Pi
release (rate constant rTL0), and the relocking step (rate
constant r45). Weiss et al. (23) suggested that when the
two tRNAs move from P/E and A/P to the E/E and P/P
states, they can un-pair from the mRNA and re-pair with
the  1 reading frame. In our model, rt represents the rate
constant for a ribosome:EF-G:GDP complex with two
tRNAs in the E- and P-sites (E0P0
EFGgdp) to re-pair with
the 1readingframe(E02P02
EFGgdp).Thismotionisrevers-
ible, as denoted by the r–t rate constant. This step is
followed by a relocking conformational change and
EF-G release from the ribosome complex. The resulting
E0P0 or E02P02 (A-site unocupied) then moves on to the
aa-tRNA selection step. Here, E0P0 is the post-
translocational ribosome aligning with deX XXY (zero
frame) and E02P02 is the post-translocational ribosome
aligning with cde XXX (–1 frame), where subscript 0
means a zero frame tRNA pairing with the zero frame;
subscript 02 means a zero frame tRNA pairing with the
 1 frame. E0P0 may generate non-frameshift product
NFS, or enter Pathway II or III described below. E02P02
can generate frameshift product FSm, which incorporates
the  1 frame aa-tRNA in the recoding site (YYY). In
addition, it is also possible for E02P02 to recruit a zero
frame aa-tRNA for YYZ (A0) and accommodate this
aa-tRNA into the  1 frame. In this case, frameshift
product FSz, which incorporates the zero frame aa-tRNA
in the recoding site (YYZ), is produced (Pathway Ia).
In the second pathway, the downstream stimulatory
structure induces ribosome pausing and promotes
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suggests that simultaneous slippage of P- and A-site
tRNAs occurs during accommodation and/or before
peptidyltransfer. In Figure 2, the process from P0A0 to
P02A02 with the rate constant kpas2 describes the slippage
in Pathway II. P02A02 then proceeds through peptidyl-
transfer to generate FSz.
InPathwayIII,incompletetranslocationoccurswhenthe
pre-translocational ribosome is positioned at XXY YYZ.
Consequently, translation of the  1 frame is one codon
downstream of YYZ and the ribosome produces FSz.I ti s
importanttonotethatwhilebothPathwayIandIIIinvolve
incomplete translocation, the Pathway I slip occurs one
elongation cycle before the Pathway III slippage event.
MATERIALS AND METHODS
Computation of the kinetic model
All pathways were mathematically described as systems of
ordinary differential equations (Supplementary Data).
Assuming steady state, the expressions of intermediate
Figure 2. The kinetic framework for programmed –1 ribosomal frameshifting. Top: the procedure from PA to E0P0 represents translocation, which
involves r1, r–1 (reversible EF-G binding), rTL0 (GTP hydrolysis, unlocking conformation change, tRNA movement and Pi release), and r45
(re-locking conformation change and EF-G dissociation). The E0P0 complex then undergoes aa-tRNA selection: from E0P0 to P0A0. The selection
of aa-tRNA involves: k1, k–1 (reversible EF-Tu binding), k2, k–2 (reversible codon recognition), k345 (GTPase activation, GTP hydrolysis, EF-Tu
conformation change and dissociation), and k6 (aa-tRNA rejection by proofreading), or k7 (aa-tRNA accommodation). The elongation cycle without
a –1 PRF event results in synthesis of non-frameshift proteins (NFS). Pathway I in green suggests that –1 PRF occurs during the relocking step in
the ﬁrst translocation, leading to the formation of FSm. Pathway Ia indicates that the E02P02 complex may interact with a zero frame aa-tRNA and
eventually produce FSz. Pathways II suggests that –1 PRF occurs during aa-tRNA selection and accommodation, resulting in FSz. Pathway III
suggests that –1 PRF occurs during the second translocation step, resulting in FSz production.
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solved by Matlab v.R2008a (Mathworks Inc., Natick,
MA, USA). By applying the empirically-determined rate
constants and assumed ranges of rate constants of incom-
plete translocation, P- and A-site tRNA slippage
(Supplementary Tables S1–S4), the amount of
non-frameshift proteins NFS (p0a0
pt in the kinetic
model) and two types of frameshift proteins, FSm
(P02A2
pt in the kinetic model) and FSz (P02A02
pt and
p02a02
pt in the kinetic model), were identiﬁed. The frame-
shift efﬁciency (FS%) in the model is deﬁned as the
amount of frameshift proteins divided by the amount of
total proteins and multiplied by 100% [Equation (1)]. The
fraction of FSm is calculated as the amount of FSm divided
by the amount of total frameshift proteins and multiplied
by 100% [Equation (2)].
FS% ¼
ðFSm+FS zÞ
ðNFS+FSm+FS zÞ
 100% ð1Þ
Fraction of FSmð%Þ¼
ðFSmÞ
ðFSm+FS zÞ
 100% ð2Þ
Sensitivity analysis
A program was developed in Matlab v.R2008a to perform
an n-way analysis of variance (ANOVA). Each parameter
in the model was varied over ﬁve levels: a base line
value,±25% of the base line, a±50% of the base line.
Randomly selected 10000 parameter sets were used to cal-
culate FS%. A higher F statistic indicates a larger impact
of the parameter on FS%.
Plasmids and bacterial strains
Escherichia coli XL1 blue MRF0 (Stratagene, La Jolla,
CA, USA) was used in all experimental studies. All con-
structs were veriﬁed by DNA sequencing at the Cornell
Bioresource Center. Construction of the dual ﬂuorescence
reporter was described earlier (27,30), except that different
linker sequences were incorporated into the reporter
plasmid (Table 1). These sequences are derived from the
frameshift signal in HIV-1 group M subtype B (22) and
the pro-pol sequence in human T-cell leukemia virus type I
(HTLV-1) (31). For the MB2 and TLV strains, the linker
sequence was made from complementary oligonucleotides
(Integrated DNA Technology, Coralville, IA, USA) and
then cloned into SalI and BamHI sites between the coding
sequence of DsRed and EGFP in the reporter plasmid.
For MB2UCC and MB2CCC strains, the nucleotide
sequence of MB2 was mutated by site-directed
mutagenesis according to the manufacturer’s protocol
(Qiagen, Valencia, CA, USA).
In vivo ﬂuorescence assay
Cells with the appropriate plasmids were cultured in 1ml
Luria-Bertani (LB) medium containing 100mg/ml ampicil-
lin with or without 0.75mg/ml chloramphenicol in 24-well
plates for 24h at 250rpm and 37 C. Fluorescence was
measured using a plate reader (SpectraMax M5,
Molecular Devices, Sunnyvale, CA, USA). Fluorescence
measurements were performed as described earlier (27).
Experimental frameshift efﬁciency (FS%exp) was obtained
as the ratio of green ﬂuorescence to red ﬂuorescence for the
test strains and normalized against the ﬂuorescence ratio of
the control strain. Statistical analyses were applied to all
data sets as described earlier (32). A total of 23–46 repli-
cates for test strains and control strains were performed to
satisfy the minimum sample requirement for statistical
signiﬁcance.
Protein puriﬁcation and trypsin digestion
Test strains were grown in 100ml LB medium containing
100mg/ml ampicillin in 500ml ﬂasks at 250rpm and 37 C.
After 24h, 200 OD600 units of cells were collected by cen-
trifugation at 4000g and 4 C for 20min. Cells were lysed
and puriﬁed by Ni-NTA under native conditions accord-
ing to the manufacturer’s protocol (Qiagen). Puriﬁed
protein samples were resolved by SDS–PAGE (10%w/v
polyacrylamide). Gel band excision and in-gel trypsin
digestion were performed using a previously described
standard method (33).
Mass spectrometry analysis
A representative ﬂow chart of the mass spectrometry
analysis is shown in Supplementary Data (Supplementary
Figure S1). Trypsin-digested frameshift protein samples
resulted in target peptides spanning the recoding sites
with a single amino acid difference between FSz and FSm.
These peptides were analysed by nano-ﬂow liquid chroma-
tography tandem mass spectrometry using multiple
reaction monitoring (nLC-MRM/MS).
The digested sample was vacuum dried, reconstituted
with 30ml of 0.1% formic acid (FA), and a portion of
each reconstituted sample was injected into Dionex 3000
nLC system (Sunnyvale, CA, USA). First, the sample was
loaded onto an Acclaim PepMap 100 C18 trap column
(300mm 5mm, 5mm) and on-line desalting was carried
out with water (0.1% FA) at a ﬂow rate of 30ml/min for
5min. Then, peptides trapped in the trap column were
Table 1. Linker sequences and corresponding E. coli strains in this study
Linker sequence between the two ﬂuorescence reporter coding sequence Strain
GCT AAT TTT TTA GGG AAG ATC TGG CCT TCC TAC AAG GGA AGG CCA GGG AAT TTT CTT GGA TAA AG MB2
GCU CCT TTT TTA GGG AAG ATC TGG CCT TCC TAC AAG GGA AGG CCA GGG AAT TTT CTT GGA TAA AG MB2UCC
GCC CCT TTT TTA GGG AAG ATC TGG CCT TCC TAC AAG GGA AGG CCA GGG AAT TTT CTT GGA TAA AG MB2CCC
TTC CCT TTA AAC CAG AAC GCC TCC AGG CCT TGC AAC ACT TGG TCC GGA AGG CCC TGG AGG CAG GCC TAA AG TLV
The heptanucleotide slippery motifs in the sequence are underlined
304 Nucleic Acids Research, 2011,Vol. 39,No. 1resolved on an Acclaim PepMap 100 C18 analytical
column (75mm 15cm, 3mm) with a gradient of 2–50%
acetonitrile with 0.1% FA over 75min. The eluent was
directly introduced into a 4000 QTRAP mass spectrom-
eter through a Nanospray II source (Applied Biosystems,
Foster City, CA, USA). For MRM, the MIDAS
Workﬂow software (Applied Biosystems) generated a list
of possible MRM transitions (Supplementary Table S5)
before MS analysis. MS and MS/MS data obtained
through MRM were searched using Mascot (34) (v. 2.2,
Matrix Science, Boston, MA, USA) within a custom
sequence database that included frameshift protein se-
quences. During the database search, the spectral assign-
ment of MS/MS was performed under parameters of MS
tolerance of 1.2Da, MS/MS tolerance of 0.6Da and
P < 0.05 and search results were manually conﬁrmed.
Peak areas of MRM transitions were calculated using
Analyst (v. 1.5, Applied Biosystems). Areas of peaks rep-
resenting different charge states of a given peptide were
summed for their usage in calculating the fraction of FSm
(%) [Equation (3)]. Samples were analysed in triplicates
(except duplicates of CCC and TLV).
Fraction of FSm ð%Þ observed by MS
¼
AFSm
AFSm+A FSz
 100%
ð3Þ
where AFSm is the sum of peak areas at different charge
states for an FSm target peptide and AFSz is the same for
an FSz target peptide in MS.
RESULTS
Mathematical model
The kinetic model allows for the evaluation of the
effects of different translation elongation cycle steps on
FS% and the fraction of FSm. Sensitivity analysis
revealed several parameters that have a greater inﬂuence
on FS% (Figure 3). Therefore, the model results will
focus on these higher impact parameters in different
pathways.
In Pathway I,  1 PRF occurs during translocation
while the pre-translocational complex is aligned with
deX XXY. Two parameters play important roles in
Pathway I in the kinetic model. Here, rt represents the
rate constant for incomplete translocation. An increase
in rt while other parameters in the model remain
constant leads to an increase in FS% (blue line in
Figure 4a). Both the levels of FSm and FSz increase
when rt increases (green and red lines in Figure 4a).
Because the rise in the FSm level is larger, increasing rt
results in a larger FSm fraction (Figure 4b). It is also inter-
esting to note that the majority of FSz comes from
Pathway III when rt is <2s
 1, while the majority of FSz
is from pathway II when rt is >2s
 1 (Figure 4b). The rate
constant r45 accounts for the relocking step during trans-
location. A decrease in r45 while other parameters in the
model remain constant results in an increase in FS% (blue
line in Figure 5a). Both the levels of FSm and FSz increase
when r45 decreases (green and red lines in Figure 5a).
However, in this case the increase in the FSm level is
larger, leading to a larger FSm fraction with a decrease
in r45 (Figure 5b). Here, the majority of FSz is from
Pathway III when r45 is <22s
 1, but the majority of FSz
results from pathway II when r45 becomes >22s
 1 (Figure
5b). These results suggest that translocation perturbations
by either a downstream mRNA secondary structure, by
mutations, or by chemical inhibitors may result in produc-
tion of a higher FS%, primarily due to production of a
larger amount of FSm. Notably, manipulating rt values
causes larger changes in FS% and in the FSm fraction
compared to the effect of r45, suggesting a dominant role
by rt on  1 PRF in Pathway I. Consistent with our model,
Figure 3. Sensitivity analysis using n-way ANOVA. A higher F-statistic
value suggests a more signiﬁcant impact of the parameter on FS%.
Nucleic AcidsResearch, 2011, Vol.39,No. 1 305experimental studies demonstrated that mutating the
E-site codon in the recoding site, or the use of a transloca-
tion inhibitor altered FS% (22).
In Pathway II,  1 PRF occurs during aa-tRNA ac-
commodation and the slippage occurs before
peptidyltransfer. Figure 6a shows that a higher kpas2
results in a higher FS%. Interestingly, the larger FS%
results from an increase in FSz while the level of FSm
remains at a similar level (Figure 6a). Therefore, the
fraction of FSm is predicted to decrease as kpas2 increases
(Figure 6b). Here, the majority of FSz is generated from
Pathway III when kpas2 is <3s
 1, while the majority of
FSz is produced from pathway II when kpas2 is >3s
 1
(Figure 6b).
In Pathway III,  1 PRF occurs during translocation
while the pre-translocational complex is aligned with
XXY YYZ. The rate constant for the incomplete transloca-
tion step is demonstrated by rt3. Figure 7a shows that a
higher rt3 promotes increased FS%. Interestingly, the
larger FS% results from an increase in FSz while the
level of FSm remains relatively constant (Figure 7a).
Therefore, the fraction of FSm is predicted to decrease
as rt3 increases (Figure 7b). In this case, the majority of
FSz is generated from Pathway II when rt3 is <1s
 1, but
the majority of FSz comes from pathway III when rt3 is
>1s
 1 (Figure 7b).
In the model, kpt represents the rate constant for
peptidyltransfer, the last step in all three pathways. The
model predicts that a decrease in kpt would result in a
higher FS% due to increased production of FSz, while
FSm synthesis remains relatively constant (Figure 8a).
Consequently, a smaller fraction of FSm is observed as
kpt decreases (Figure 8b). In this scheme, the majority of
FSz is synthesized from Pathway II when kpt is <15s
 1,
while the majority of FSz comes from pathway III when
kpt is >15s
 1 (Figure 8b). The model results are consistent
Figure 4. The effect of incomplete translocation during the ﬁrst elong-
ation cycle (represented by rt) on –1 PRF. All other parameters are
assumed to be constant. (a) The effect of rt on frameshift efﬁciency
(FS%, blue line), frameshift protein incorporating a –1 frame aa-tRNA
at the recoding site (FSm, green line), and frameshift protein
incorporating a zero frame aa-tRNA at the recoding site (FSz, red
line). (b) The effect of rt on the fraction of FSm and FSz.
Figure 5. The effect of the relocking step during translocation (repre-
sented by r45) on –1 PRF. All the other parameters are assumed to be
constant. (a) The effect of r45 on the level of frameshift efﬁciency
(FS%, blue line), frameshift protein incorporating a –1 frame
aa-tRNA at the recoding site (FSm, green line), and frameshift
protein incorporating a zero frame aa-tRNA at the recoding site
(FSz, red line). (b) The effect of r45 on the fraction of FSm and FSz.
306 Nucleic Acids Research, 2011,Vol. 39,No. 1with previous experimental observations that peptidyl-
transferase inhibitors affect FS% (35).
Experimental results
To examine the model predictions,  1 PRF efﬁciency was
monitored in vivo using a dual ﬂuorescence reporter
system. In addition, compositions of the frameshift
protein products were analysed by mass spectrometry.
Analysis of the frameshift products revealed that the
ratio of FSz to FSm was  4:1 in MB2 cells (Figure 9),
thus indicating that the vast majority of  1 PRF events
naturally occur through Pathways II and/or III. The
model predicts that a smaller kpt should cause higher
FS% and a lower fraction of FSm (Figure 8). A prior
study using yeast demonstrated that inhibition of
peptidyltransfer promoted increased rates of  1 PRF,
but did not differentiate between FSm and FSz
products (36). The model predicts that addition of
chloramphenicol, a potent peptidyltransferase inhibitor
in bacteria (37), should promote increased FS%.
Consistent with the model, a 2.1-fold increase in FS%exp
was observed in the E. coli culture containing 0.75mg/ml
chloramphenicol compared to the culture without the
drug. The fractions of FSm for the culture with and
without chloramphenicol were 17.3 and 20.4%, respective-
ly (Figure 9a). Although a slight decrease in the fraction of
FSm was observed in the presence of the drug, the differ-
ence was not statistically signiﬁcant (P > 0.05).
The frameshift sequence for HIV-1 is U AAU UUU UUA,
where a space separates each zero frame codon and the
P-site of the recoding site is underlined. The E-site
tRNAGUU
Asn may form one canonical base pairing with
the  1 frame UAA. In the MB2UCC strain, the sequence
was mutated to UC C U UUU UUA (mutations shown in
bold) where the E-site tRNAGGG
Pro can potentially form
one G:U and two C:G interactions. In the MB2CCC
strain, the sequence was mutated to CC C U UUU UUA
Figure 6. The effect of the slippage of P- and A-site tRNAs before
peptidyltransfer (represented by kpas2) on –1 PRF. All the other par-
ameters are assumed to be constant. (a) The effect of kpas2 on the level
of frameshift efﬁciency (FS%, blue line), frameshift protein
incorporating a –1 frame aa-tRNA at the recoding site (FSm, green
line), and frameshift protein incorporating a zero frame aa-tRNA at
the recoding site (FSz, red line). (b) The effect of kpas2 on the fraction of
FSm and FSz.
Figure 7. The effect of incomplete translocation during the second
elongation cycle (represented by rt3) on –1 PRF. (a) The effect of rt3
on the level of frameshift efﬁciency (FS%, blue line), frameshift protein
incorporating a –1 frame aa-tRNA at the recoding site (FSm, green
line), and frameshift protein incorporating a zero frame aa-tRNA at
the recoding site (FSz, red line). (b) The effect of rt3 on the fraction of
FSm and FSz.
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Pro
can form three canonical base pairings with the  1 frame
CCC. Because Pathway I requires that the E- and P-site
tRNAs interact with the  1 frame, UCC and CCC as the
 1 frame E-site codons may enhance this reaction, i.e.
these codons would promote an increase in rt. The
model predicts that a larger rt should result in a higher
FS% due to increased production of FSm. Consistently,
1.2- and 1.4-fold increase in FS%exp are observed for the
MB2UCC and MB2CCC strains compared to the MB2
strain, respectively (Figure 9b). In the MB2UCC strain,
76.4% of the frameshift products were FSm, and in the
MB2CCC strain, 90.3% of the frameshift products were
FSm. These results suggest that changing the sequence to
favor incomplete translocation, i.e. to favor Pathway I,
can dramatically alter the composition of the frameshift
product.
To further our understanding of two types of frameshift
proteins, the HTLV-1 pro-pol frameshift sequence was
cloned into the reporter system. The extended frameshift
sequence for HTLV-1 pro-pol is C CCU UUA AAC (where
spaces separate zero frame codons and the slippery
sequence is underlined). Similar to MB2CCC, the E-site
tRNAGGG
Pro can potentially form three canonical base
pairings with the  1 frame CCC, which may create a fa-
vorable condition for Pathway I. Consequently, a signiﬁ-
cant amount of FSm among total frameshift proteins can
be produced. Consistent with the model, the frameshift
efﬁciency for HTLV-1 was 4.81% and the fraction of
FSm was 39.4%.
DISCUSSION
In this study, a mathematical framework was developed
for  1 PRF. To our knowledge, this is the ﬁrst kinetic
model to explain the production of two types of  1 frame-
shift proteins through three distinct kinetic pathways.
Using deX XXY YYZ fgh as an example, Pathway I
predicts that a pre-translocational ribosome aligning
with deX XXY may shift reading frame during incomplete
translocation, producing the frameshift product (FSm)
incorporating a  1 frame aa-tRNA in the frameshift site
(codon YYY). Additionally, Pathway II predicts that a
ribosome can change reading frame due to simultaneous
slippage of P- and A-site tRNAs for a ribosome aligning
with XXY YYZ, generating a frameshift product (FSz)
incorporating the zero frame aa-tRNA in the frameshift
site (codon YYZ). Lastly, in Pathway III, a pre-
translocational ribosome aligning with XXY YYZ may
also undergo incomplete translocation to generate FSz.
The kinetic model suggests that incomplete transloca-
tion of the pre-translocational ribosome aligning with deX
XXY produces FSm. Previous studies suggested that FSm
may result from slippage of a single P-site tRNA (1,25,26).
However, it is not clear when and/or how this could occur.
In addition, the single slippage model does not explain
experimental evidence regarding the inﬂuence of trans-
location on  1 PRF (22,23). Our model suggests that in
both mechanisms, incomplete translocation and slippage
of P- and A-site tRNAs participate in synthesizing frame-
shift proteins to varying extents for different  1 PRF
signals. Frameshifting at the HIV-1 sequence was
reported to generate  70% FSz and 30% FSm (1,25),
indicating that Pathways II and/or III exert stronger in-
ﬂuence on FS% than Pathway I. Notably, our protein
analysis showed  80% FSz and 20% FSm for the frame-
shifting signal in HIV-1 group M subtype B. This small
discrepancy may due to the use of different reporter
systems, or differences in the quantitative methods
employed for the assay. For the HTLV-1 pro-pol frame-
shift sequence, this study observed 39.4% FSm in total
frameshift protein. This is the ﬁrst study to demonstrate
another frameshift sequence that generates a signiﬁcant
amount of FSm in addition to HIV-1. Interestingly, a
small but observable lysine peak appeared at the corres-
ponding position (–1 frame A-site codon in the recoding
site) when HTLV-1 pro-pol frameshift proteins were
sequenced in the previous study (31), supporting the pro-
duction of FSm. The stimulatory RNA of HTLV-1 pro-pol
Figure 8. The effect of the peptidyltransfer (represented by kpt)o n– 1
PRF. All the other parameters are assumed to be constant. (a) The
effect of kpt on the level of frameshift efﬁciency (FS%, blue line),
frameshift protein incorporating a –1 frame aa-tRNA at the recoding
site (FSm, green line), and frameshift protein incorporating a zero frame
aa-tRNA at the recoding site (FSz, red line). (b) The effect of kpt on the
fraction of FSm and FSz.
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direct evidence for the RNA structure was shown in the
same study. Interestingly, the mouse Edr frameshift
sequence, which shares high similarity with the HTLV-1
pro-pol sequence, was suggested to involve a pseudoknot
(38). Because the length of HTLV-1 pro-pol stimulatory
signals is not well-deﬁned, the frameshift sequence
incorporated in the TLV strain may not represent the
whole stimulatory signal. However, the possible absence
of a portion of the stimulatory signal did not prevent us
from observing a signiﬁcant amount of frameshift efﬁ-
ciency and the ratio of FSm to the total frameshift
protein. Frameshift products from other  1 PRF signals
were analysed previously (39,40). For SARS-CoV frame-
shifting, FSm was not found (39). However, for the
Alphavirus coding sequence 6k, both FSz and FSm were
identiﬁed in the frameshift products, although the exact
ratio was not determined (40).
The current study shows that all three kinetic pathways
are operative during  1 PRF. For HIV-1 and HTLV-1,
experimental results indicate that 20.4 and 39.4%, respect-
ively, of frameshift proteins are FSm, i.e. the contribution
of Pathway I. Although the experimental approach can-
not differentiate between the relative contributions of
Pathways II and III to FSz production, the kinetic
model can be used to discriminate between the effects of
these two pathways. In the kinetic model, rt, kpas2 and rt3
represent non-regular events, which are likely to be rate-
limiting steps. These rate constants are thus expected to be
small. The values for r45 and kpt are 5 and 50s
 1, respect-
ively (Supplementary Tables S1 and S2). As shown in
Figures 4–8, rt, r45, kpas2, and rt3 are all in the small
value ranges, and kpt at 50s
 1, suggest that Pathway III
contributes approximately equal or more to the FSz pro-
duction than does Pathway II. Interestingly, inhibition of
peptidyltransfer (decreasing kpt) can switch to a condition
in which Pathway II contributes more to FSz production
than Pathway III (Figure 8b). These ﬁndings are consist-
ent with the hypothesis that the  1 PRF signals of differ-
ent viruses have evolved within these kinetic parameters so
as to produce the optimal ratios of shifted to unshifted
products according to their speciﬁc biological
requirements.
The effect of incomplete translocation can be under-
stood in two ways. Incomplete translocation at the
pre-translocational ribosome aligning with deX XXY
produced more FSm (Pathway I), consistent with the
model by Leger et al. (22). Incomplete translocation at
the pre-translocational ribosome aligning with XXY YYZ
resulted in more FSz (Pathway III), consistent with the
models proposed by Weiss et al. (23) and Namy et al.
(24). Enhancing incomplete translocation in Pathway I
promoted an increase in the fraction of FSm among total
frameshift proteins. On the other hand, enhancing incom-
plete translocation in Pathway III decrease the fraction of
FSm. While these two pathways were supported by
previous studies, the direct observation of FSm for
HIV-1 and HTLV-1 pro-pol frameshift sequences
provided proof for the validity of Pathway I.
Interestingly, altering the extended frameshift sequence
resulted in a signiﬁcant change in frameshift protein com-
positions, supporting the role of the sequence upstream of
the traditional slippery site XXY YYZ.
In the presence of chloramphenicol, a 2.1-fold increase
in FS%exp was observed while the fraction of FSm was not
signiﬁcantly different compared to the culture condition
without the chemical (Figure 9a). The model predicts that
kpt has a relatively smaller effect on FS% and the fraction
of FSm than rt and kpas2 (Figure 8). A dual ﬂuorescence
reporter can sensitively detect small changes in FS% in
E. coli and mammalian cells (27,30,41). On the other
hand, analysing the composition of the frameshift
products relies on multiple manipulations including
protein puriﬁcation, gel electrophoresis, in-gel digestion,
Figure 9. Experimentally perturbing the system results in different levels of frameshift efﬁciency (FS%exp) and the fraction of FSm. The total height
of the column represents FS%exp. The white and the dark portions in columns show the fraction of FSm and FSz, respectively. The value for the
fraction of FSm is also shown under each column. Error bars indicate the standard deviation for FS%exp.( a) The presence of chloramphenicol (Cm)
results in higher FS%exp. The fraction of the FSm with and without the drug is not signiﬁcantly different (P>0.05). (b) The MB2UCC and MB2CCC
strains results in higher FS%exp and FSm fraction compared to MB2 (linker sequences listed in Table 1).
Nucleic AcidsResearch, 2011, Vol.39,No. 1 309liquid chromatography and mass spectrometry. The multi-
stage preparation may thus affect sample yields,
complicating the detection of small changes in protein
composition.
A signiﬁcant increase in the fraction of FSm was
observed in both MB2UCC and MB2CCC strains
(Figure 9b). Mutation of the  1 frame E-site sequence
to UCC and CCC in the HIV-1 frameshift site may
enhance incomplete translocation in Pathway I by
allowing more interactions between E-site tRNA and the
 1 frame. This result is consistent with the model that
different mechanisms exist and participate in making
frameshift proteins to different extents. The creation of
a favorable condition for one pathway can affect the
composition of frameshift proteins signiﬁcantly. To date,
no mutations affecting the composition of frameshift
proteins have been reported in the literature. Notably,
our experimental results show that in one case, FS% in-
creases signiﬁcantly without a change in the composition
of frameshift products (Figure 9a), while in another
condition FS% increases a smaller amount but the
composition of frameshift products change dramatically
(Figure 9b).
Several parameters in the kinetic model, such as rt, r–t,
kpas2, k–pas2, rt3 and r–t3, have not been measured experi-
mentally in the literature. The test ranges for these par-
ameters are based on our current kinetic understanding
of translation elongation. The rate constants for trans-
location and aa-tRNA selection range from 0.47 to
1980s
 1 (Supplementary Tables S1–S4). The average
protein synthesis rate is 10–20s
 1 in prokaryotic cells
but some codons are translated at a rate <10s
 1 (42).
Therefore, a broad range (1–100s
 1), within the scope of
the known elongation rate constants, was tested to
understand the impact each of these unknown param-
eters on  1 frameshifting (Figures 4, 6 and 7).
Notably, these ﬁgures do not show the impact of these
parameters >100s
 1 because the curves level off for the
parameters at this range.
Although the investigation of whether the slippage of
the two tRNAs is a simultaneous or a sequential process is
beyond the scope of this study, a similar kinetic approach
Figure 10. The effect of the rate constants related to sequential tRNA movement (a) rt1,( b) r–t1,( c) rt2, and (d) r–t2 on the rate constants related to
single step sequential tRNA movement (rt and r–t). The base point is assumed as rt1=1s
 1, r–t1=10s
 1, rt2=1s
 1, and r–t2=10s
 1. The inset in
(d) shows a zoom in of the plot.
310 Nucleic Acids Research, 2011,Vol. 39,No. 1can be used to understand the effect of sequential tRNA
movement on the overall process. Using the movement of
E- and P-site tRNAs as an example, the overall movement
and the sequential movement can be described as the
following:
One step tRNA movement (Rx.1)
E0P
EFGgdt
0   !
rt
r t
E02 P
EFGgdt
02
Sequential tRNA movement (Rx.2)
E0P
EFGgdt
0   !
rt1
r t1
E02P
EFGgdt
0   !
rt2
r t2
E02P
EFGgdt
02
Assuming steady state, rt and r–t can be represented by rt1,
r–t1, rt2 and r–t2 (Supplementary Data). Figure 10 shows
how a change in the rate constants in Rx.2 can affect the
overall rate constants in Rx.1. The result suggests that
repositioning of the E-site tRNA to the  1 frame (repre-
sented by rt1) may have a larger impact than repositioning
of the P-site tRNA (represented by rt2) on the slippage
toward the  1 frame (represented by rt). On the other
hand, repositioning the P-site tRNA back to zero frame
(represented by r–t2) may have larger impact than repos-
itioning the E-site tRNA (represented by r–t1) on the
slippage toward the zero frame (represented by r–t).
Similarly, the same observation also applies to the
movement for P- and A-site tRNAs (kpas2, and k–pas2)i n
the model.
CONCLUSION
A mathematical framework developed upon the transla-
tion elongation cycle revealed three distinct kinetic
pathways for  1 PRF. The model describes how al-
terations of these kinetic parameters can affect not only
changes in frameshift efﬁciency, but also changes in the
composition of frameshift products under different condi-
tions. In addition, the model identiﬁes the dominant par-
ameters, representing steps in the translation elongation
cycle, on  1 PRF. Experimentally targeting these steps
resulted in different levels of frameshifting efﬁciency, con-
sistent with model predictions. A mutation in the  1
frame E-site sequence was shown to dramatically change
the composition of frameshift products, suggesting an im-
portant role for the sequence upstream of the slippery site.
Our results suggest that not only the frameshift efﬁciency,
but also the compositions of the frameshift products, are
worth investigating to advance our knowledge of  1 PRF.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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